Western blotting and quantifications. Chondrocytes were treated with control, TNF-α (50 ng/mL), or CDDO-Im (20 nM) plus TNF-α in the presence or absence of ML385 (20 μM) for 24 h, and then the protein expression (a) and quantification (b) of ATG7, P62, Beclin1 and LC3 I/II were assessed. c Representative Western blot of Nrf2, ATG7, P62, Beclin1 and LC3 I/II in chondrocytes pretreated with CDDO-Im (20 nM) with or without TNF-α (50 ng/mL) in the presence of siControl (siCtrl) or siNrf2 for 24 h. d Quantitative analysis of the protein levels in Fig. 8c. The values are presented as the means ± SDs. *P < 0.05 versus control, #P < 0.05 versus TNF-α-treated chondrocytes, †P < 0.05 versus TNF-α- and CDDO-Im-treated chondrocytes.